Edwards Lifesciences Reports 11.9% Net Sales Increase to $1.53 Billion in Q2 2025

Edwards Lifesciences Corporation reported a net sales increase of 11.9% for the second quarter of 2025, reaching $1.53 billion, compared to $1.37 billion in the same period of 2024. For the first half of 2025, net sales totaled $2.94 billion, up from $2.70 billion in the prior year. The company's gross profit for the second quarter was $1.19 billion, reflecting a gross margin of 77.5%, although this was a slight decrease from the previous year due to higher manufacturing costs and foreign currency fluctuations. Net income attributable to Edwards Lifesciences for the second quarter was $333.2 million, or $0.56 per diluted share, down from $366.3 million, or $0.61 per diluted share, in the same quarter of 2024.

The company experienced significant growth in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines, with TAVR sales increasing by 8.9% to $1.13 billion in the second quarter. TMTT sales surged by 61.9% to $134.5 million, driven by the successful launch of new products. Edwards Lifesciences also reported a loss on impairment of $47.1 million related to an option not exercised for a cost method investment. The company’s operating income for the second quarter was $411.2 million, compared to $366.5 million in the prior year.

In terms of strategic developments, Edwards Lifesciences completed the sale of its Critical Care product group in September 2024, which has been classified as discontinued operations. The company is also in the process of selling a non-core product group, with the transaction expected to close in 2025. The transition services agreement related to the Critical Care sale generated $19.9 million in income for the second quarter. Edwards Lifesciences continues to focus on expanding its product offerings in structural heart disease, with recent FDA approvals for new therapies.

Operationally, the company reported a total employee headcount of approximately 15,000 as of June 30, 2025, reflecting a slight increase from the previous year. Edwards Lifesciences is also actively managing its cash flow, with cash and cash equivalents totaling $3.27 billion at the end of the second quarter, up from $3.05 billion at the end of 2024. The company’s cash flow from operating activities increased significantly to $570.6 million for the first half of 2025, compared to $318.0 million in the same period of 2024, primarily due to lower tax payments and improved operational performance.

Looking ahead, Edwards Lifesciences anticipates continued growth driven by its innovative product pipeline and strategic focus on structural heart disease. However, the company acknowledges potential challenges from global market conditions, including tariff impacts and competition. The effective income tax rate for the company is expected to rise due to new global minimum tax regulations, which may result in additional tax expenses. Overall, Edwards Lifesciences remains committed to enhancing patient outcomes through its advanced medical technologies while navigating the complexities of the healthcare landscape.